Chronic Rhinitis Solution NEUROMARK Secures €62.5 Million as Irish Startup Neurent Medical Closes Series C
•February 12, 2026
0
Why It Matters
The capital fast‑tracks deployment of a clinically validated, minimally invasive therapy for a condition affecting millions, highlighting strong market demand for innovative ENT solutions.
Key Takeaways
- •€62.5M Series C led by MVM, Sofinnova.
- •NEUROMARK treats chronic rhinitis via impedance‑controlled RF.
- •Funding fuels EU commercial expansion and new indications.
- •Board adds MVM and Sofinnova partners.
- •Highlights growing MedTech investment in Europe.
Pulse Analysis
Chronic rhinitis impacts a sizable global patient base, yet treatment options remain limited to pharmacotherapy and surgery, both of which carry compliance or safety concerns. NEUROMARK’s proprietary impedance‑controlled radiofrequency technology offers a targeted, minimally invasive approach that disrupts overactive posterior nasal nerves, delivering durable symptom relief with minimal downtime. Early clinical data suggest a favorable safety profile, positioning the device as a potential new standard of care for ENT specialists seeking to address the root cause rather than merely managing symptoms.
The €62.5 million Series C injection, spearheaded by MVM Partners and Sofinnova, signals robust investor confidence in Neurent’s commercial strategy and technology differentiation. In a funding climate where European MedTech startups typically raise between €5 million and €20 million, Neurent’s raise sits at the high end, reflecting both the market size of chronic rhinitis and the perceived scalability of its platform. The capital will fund regulatory submissions, expand sales infrastructure across key European markets, and generate additional real‑world evidence to strengthen reimbursement pathways.
Looking ahead, Neurent aims to leverage its impedance‑control platform beyond chronic rhinitis, exploring adjacent indications in sinonasal inflammation and potentially other peripheral nerve disorders. The addition of MVM and Sofinnova partners to the board brings strategic guidance and deep industry networks, accelerating partnership opportunities and future fundraising. As MedTech investors increasingly prioritize devices with clear clinical outcomes and scalable business models, Neurent’s trajectory may set a benchmark for Irish and broader European health‑tech ventures seeking to translate innovative engineering into measurable patient benefit.
Chronic rhinitis solution NEUROMARK secures €62.5 million as Irish startup Neurent Medical closes Series C
Galway-based Neurent Medical, the company behind NEUROMARK, a minimally invasive solution to treat chronic rhinitis, today announced the successful close of its oversubscribed Series C financing, raising €62.5 million ($74 million) to drive commercial expansion, broaden clinical evidence, and advance its product and indication pipeline.
The financing was led by MVM Partners, with significant participation from Sofinnova Partners, and included continued support from existing investors EQT Life Sciences, Atlantic Bridge, Fountain Healthcare Partners and Enterprise Ireland.
“I am delighted to welcome MVM Partners and Sofinnova Partners to the Neurent Medical team, two global leaders in MedTech investing,” says CEO of Neurent Medical, Brian Shields. “This Series C financing will support our commercial expansion and help bring NEUROMARK to the patients and physicians who need it most.”
In the European HealthTech and MedTech funding landscape in 2025–2026, a number of startups have secured significant capital to advance clinical technologies and healthcare solutions:
-
SamanTree Medical (Liège, Belgium) raised €20 million in EIB-backed financing to support development and commercialisation of its real-time surgical imaging device
-
Recare (Berlin, Germany) closed €37 million in growth funding to scale its AI-driven hospital workflow platform internationally
-
Smaller rounds like PIUR IMAGING (Vienna, Austria), which raised €5.6 million for tomographic 3D ultrasound technology, and Juisci (Paris, France), which raised €5.5 million for an AI clinician support platform.
Set against that context, Neurent Medical’s €62.5 million Series C places it at the higher end of European MedTech fundraising in this period, highlighting investor confidence in companies developing clinically validated devices and treatments for chronic conditions where existing options are limited.
“Millions of patients suffer from chronic rhinitis, and posterior nasal nerve ablation represents a powerful tool to provide proven relief,” adds Kyle Dempsey, Partner at MVM Partners. “In this rapidly emerging category, Neurent has set a new standard with a best-in-class solution, powered by a proprietary impedance control system that delivers real-time feedback, giving clinicians greater treatment confidence, control, and predictability during every procedure.”
Founded in 2015, Neurent Medical is dedicated to transforming the treatment landscape for chronic inflammatory sinonasal diseases. Its flagship NEUROMARK System utilises proprietary Impedance Controlled Radiofrequency technology to gently disrupt hyperactive posterior nasal nerves, reportedly delivering durable symptom relief from chronic rhinitis with minimal downtime and a strong safety profile.
According to the company, chronic rhinitis affects millions of people worldwide and is characterised by persistent symptoms including nasal congestion, rhinorrhea (runny nose), sneezing and postnasal drip that can significantly diminish quality of life.
NEUROMARK’s proprietary Impedance Controlled Radiofrequency technology targets the overactive posterior nasal nerves (PNN) that drive these symptoms, providing clinicians with a differentiated and durable treatment option designed to “address the root cause, not just manage symptoms“.
Neurent Medical also welcomed Kyle Dempsey, Partner at MVM Partners, and Cedric Moreau, Partner at Sofinnova Partners, to its Board of Directors.
“Chronic rhinitis is a widespread and often overlooked condition affecting millions of patients with limited effective treatment options. Neurent Medical has developed a truly differentiated approach supported by a growing body of clinical evidence demonstrating meaningful and durable patient benefit,” adds Cedric Moreau. “We also see significant potential to expand this platform into additional indications, and we are confident in our partnership with Neurent Medical at this pivotal stage of commercial growth.”
The post Chronic rhinitis solution NEUROMARK secures €62.5 million as Irish startup Neurent Medical closes Series C appeared first on EU-Startups.
0
Comments
Want to join the conversation?
Loading comments...